Applications
Antibody Design
Enzyme Engineering
Vaccine Design
Whether building entirely novel proteins from scratch or reengineering your existing candidates, our team combines cutting-edge computational methods with deep structural and functional expertise to deliver proteins that perform. Central to our capabilities is the de novo design of high-affinity binders targeting any disease-relevant protein of interest — from GPCRs to circulating proteins and beyond — opening new therapeutic avenues where conventional approaches fall short. Whatever your target, whatever your challenge, we engineer the protein your project demands.
If you have a hit for a specific target and want to design an antibody from scratch, please don’t hesitate to contact us. We talk antibody language!
The antibody market gets bigger every year with 4 of the top 10 best-selling pharmaceuticals in 2022 being antibodies (with an year dominated by sales of COVID vaccines) with revenues higher than ~10 billion USD. However, the computational discovery and design of antibodies are still in their infancies, with thorough experimental validation and serendipity still being the main ways to develop an antibody. We know that this field will benefit a lot from generative AI tools combined with MM techniques to design novel antibodies in a more cost-efficient manner. We can work with different antibody formats, including IgG, Fab, ScFv, VHH, VNAR, and bispecifics. Feel free to contact us if you want to try our automated toolkit for in silico antibody discovery.
Our technologies allow us to design vaccines for both sequential and conformational epitopes. You need a vaccine, you have it!
We are redefining the limits of vaccinology through cutting-edge computational engineering. Our proven track record is anchored by the successful VRSVAC project, which resulted in a successful vaccine candidates with HIPRA and demonstrated our ability to translate complex design into tangible biomedical assets. Building on this momentum, our current initiatives, EpiVac and RAPID-VAC, push the boundaries of responsiveness. While EpiVac focuses on sophisticated epitope discovery for Porcine Reproductive and Respiratory Syndrome Virus, RAPID-VAC represents a paradigm shift: the creation of a fully automated platform capable of designing a vaccine candidate against any “Pathogen X” in just one week. By integrating state-of-the-art AI tools, structural biology with high-performance computing, Nostrum provides the agility and precision required to stay ahead of global health threats, transforming months of R&D into days of decisive action.
We have expertise in designing molecules that bind to the target of interest, including small/medium-size proteins. Tell us what you need.
Our expertise has been proven in a joint publication with Navigo Proteins GmbH where we successfully designed accelerated the binding protein discovery campaign. We also have recently got a top 10 position in an international competition aiming at designing binders for Nipah Virus Glycoprotein. Thus, feel free to contact us if you have a related problem, we will provide assistance.
Are you looking for an enzyme that can perform your reaction of interest under specific conditions? Contact us.
Our unique AI + MM pipelines will allow you to quickly find the enzyme you are looking for with thousands of sequences assayed computationally. Moreover, we have our own protein language model that can be fine-tuned to your specific enzyme family, so we can generate sequences and use it to infer a smart library of mutations.
Looking for a multitasking enzyme? Ask us to design your tailored PluriZymes for your industrial processes needs.
De novo active sites: new functionalities, new opportunities. Through computer-aided rational design, we can design an enzyme that supports multiple chemistries, allowing cascade reactions in a single protein scaffold. Thanks to this revolutionary idea, we have published several articles, including in Nature Catalysis
The video shows how we use PELE to explore non-functional binding sites in proteins and functionalize them through site-directed mutagenesis by adding the catalytic triad of a serine hydrolase.
